论文部分内容阅读
262例原发性肝癌行经导管肝动脉注射碘油抗癌药混悬剂栓塞化疗（LP－TAE）后随访4～5年，生存3年以上52例，其中27例生存4年以上，8例生存5年以上，3、4、5年累计生存率分别为21．04％，11．64％和4．03％（寿命表法）。与同期生存3年以内的210例对照比较，结果表明病程分期、肝功能、肿瘤大小与生长方式、肿瘤供血丰富程度、是否伴有门脉癌柱与A－V分流、是否加用明胶海绵栓塞、Lp－TAE后碘油沉积范围、治疗后肿瘤缩小程度、AFP是否降为正常、是否伴发肝内外转移是影响肝癌Lp－TAE远期疗效的重要因素。
262 cases of primary hepatic carcinoma undergoing transcatheter hepatic artery injection of lipiodol anticancer drug suspension embolization chemotherapy (LP-TAE) followed up for 4 to 5 years and survived for more than 3 years in 52 cases, of which 27 cases survived for more than 4 years, 8 cases Over 5 years of survival, cumulative survival rates at 3, 4 and 5 years were 21.04%, 11.64% and 4.03% (life table method). Compared with the 210 controls within the same period of survival within 3 years, the results showed that the disease stage, liver function, tumor size and growth pattern, tumor blood supply richness, whether accompanied by portal cancer and A-V shunt, whether the use of gelatin sponge embolism The extent of lipiodol deposition after Lp-TAE, the extent of tumor shrinkage after treatment, whether AFP is reduced to normal, and whether intrahepatic metastasis is associated with liver cancer are important factors affecting the long-term efficacy of Lp-TAE.